None listed
Conditions
Brief summary
The purpose of this study is to determine whether certain biomarkers have an impact on the effectiveness of treatment of bladder cancer. Who is it for? You may be eligible for this study if you are over the age of 18 and have been diagnosed with bladder cancer or urinary tract cancer. Study details All participants will be required to give blood and urine samples at predetermined time points while completing their own cancer treatment. Where possible, blood collection will be at the same time as routine blood tests to reduce the number of times blood is taken. If there is left over tissue after planned medical procedures then a sample of this tissue will be kept. The blood, urine and tissue samples will then be tested to determine how the cells, genes and immune system interact with the cancer and whether these relate to treatment results. It is hoped that this research will help us to better understand why some bladder and urinary tract cancers are more aggressive than other and also why some treatments work better in some patients than others.
Interventions
Enrolled patients diagnosed with muscle-invasive or metastatic bladder (urothelial or non-urothelial) cancer will undergo collection of clinical data and archival tumour specimens. Clinical data collected includes: patient demographics and characteristics, disease clinicopathological and molecular features, treatment history, outcomes and survival. Data will be collected regularly throughout the patient's treatment and follow up until death. Where applicable, patients will also undergo collectio
Enrolled patients diagnosed with muscle-invasive or metastatic bladder (urothelial or non-urothelial) cancer will undergo collection of clinical data and archival tumour specimens. Clinical data collected includes: patient demographics and characteristics, disease clinicopathological and molecular features, treatment history, outcomes and survival. Data will be collected regularly throughout the patient's treatment and follow up until death. Where applicable, patients will also undergo collection of tissue, blood and urine at several time points
Sponsors
Walter and Eliza Hall Institute for Medical Research
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must meet the following criteria to be eligible for inclusion in this protocol: Any patient with a diagnosis of bladder (urothelial or non-urothelial) cancer or other urinary tract cancer (including upper tract primary or urethral primary). Age 18 years or above. If consent to the collection of blood and urine samples: Able to undergo collection of blood and/or urine specimens.
Exclusion criteria
None
Outcome results
None listed